COMBATing airway inflammation in infants with cystic fibrosis
- PMID: 35662407
- DOI: 10.1016/S2213-2600(22)00216-8
COMBATing airway inflammation in infants with cystic fibrosis
Conflict of interest statement
FR declares grants, consulting, or honorarium from Vertex, and has acted as a consultant for Proteostasis, TranslateBio, Boehringer Ingelheim, and Calitheria, for activities related to cystic fibrosis. MR declares no competing interests.
Comment on
-
The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial.Lancet Respir Med. 2022 Aug;10(8):776-784. doi: 10.1016/S2213-2600(22)00165-5. Epub 2022 Jun 2. Lancet Respir Med. 2022. PMID: 35662406 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical